icotrokinra

Icotrokinra is an investigational **oral targeted peptide** that selectively antagonizes the **interleukin-23 receptor** and is being developed primarily for immune-mediated inflammatory diseases. The asset was jointly discovered by **Protagonist Therapeutics** and **Johnson & Johnson**, with Protagonist leading development through Phase 1 and Johnson & Johnson holding exclusive worldwide rights for Phase 2 onward development and commercialization. Clinically, icotrokinra has emerged as a late-stage program in **plaque psoriasis**, with additional development in **psoriatic arthritis**, **ulcerative colitis**, and **Crohn's disease**. It is described as a first-in-class oral IL-23 receptor blocker and has shown strong Phase 3 efficacy in moderate-to-severe plaque psoriasis, including superiority over deucravacitinib in the ICONIC-ADVANCE studies and advancement into a head-to-head Phase 3 study against ustekinumab.

Brand names

ICOTYDE

Other names

icotrokinra